NCT01481129已完成2 期
A Phase 2 Study of MK-2206 in Patients With Relapsed or Refractory Diffuse Large-B Cell Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 9
- 主要终点
- Objective Response Rate According to the International Response Criteria for DLBCL (Cheson 2007)
研究概览
简要总结
This phase II trial is studying how well Akt inhibitor MK2206 works in treating patients with relapsed or refractory diffuse large B-cell lymphoma. Akt inhibitor MK2206 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
详细描述
PRIMARY OBJECTIVES:
I. To evaluate the antitumor activity of Akt inhibitor MK2206 (MK2206) in terms of objective response rate (ORR) at 4 months (complete response [CR], and partial response [PR]) as per the 2007 International Cheson response criteria.
SECONDARY OBJECTIVES:
I. To evaluate the antitumor activity of MK2206 in terms of ORR at 4 months (CR, unconfirmed complete response [CRu], and PR) as per the 1999 International Cheson response criteria.
II. To determine the duration of response, defined as the time from the date of the best response to the date of progression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed diffuse large B-cell lymphoma
- •Relapsed or refractory disease
- •Measurable disease
- •At least one measurable lymph node mass that is > 1.5 cm in two perpendicular dimensions and that has not been previously irradiated or has grown since previous irradiation
- •Dominant lymph node masses include up to 6 nodal masses that are clearly measurable in 2 perpendicular dimensions and > 1.5 cm in each dimension
- •Measurement may be by radiographic imaging
- •If there are lymph node masses in the mediastinum or pelvis larger than 1.5 cm in 2 perpendicular dimensions, they should always be chosen as dominant masses
- •The dominant masses should be from as disparate regions of the body as possible
- •Measurable sites of disease are also extra-nodal sites such as splenic nodules and hepatic nodules that are thought to contain lymphoma, and are greater than 1 cm in the longest transverse dimension
- •Must have received at least two prior treatment lines; there is no maximal limit on the number of prior therapies
- •Prior treatment must include CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone)-like chemotherapy in combination with rituximab
- •Rituximab used alone is not considered as a separate regimen
- •Salvage treatment, mobilization chemotherapy, high-dose chemotherapy, and planned post-transplant therapy should be considered as one regimen
- •Relapsed or refractory patients who are candidates for high-dose chemotherapy and autologous or allogeneic stem cell transplantation are not eligible
- •Tumor tissue sample must be available for pathological review
- •No known CNS involvement
- •ECOG performance status < 2 (Karnofsky > 60%)
- •Life expectancy > 4 months
- •Absolute neutrophil count >= 1,500/µL
- •Platelets >= 100,000/µL (>= 75,000/µL if the bone marrow is involved)
- •Total bilirubin =< 1.5 X institutional upper limit of normal (ULN)
- •AST(SGOT)/ALT(SGPT) =< 2.5 X ULN
- •Calculated creatinine clearance >= 50 mL/min
- •Not pregnant or nursing
- •Negative pregnancy test
- •Women of child-bearing potential and men must agree to use adequate contraception
- •Must be able to swallow whole tablets
- •Nasogastric or G-tube administration is not allowed
- •Tablets must not be crushed or chewed
- •Patients with French Social Security in compliance with the French law relating to biomedical research allowed
- •No history of allergic reactions attributed to compounds of similar chemical or biologic composition to MK2206 tablets
- •Hyperglycemia should be well controlled on oral agents
- •Cardiovascular baseline QTcF =< 450 msec (male) or QTcF =< 470 msec (female)
- •No uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- •No HIV-positive patients on combination antiretroviral therapy
- •No patients with malabsorption syndrome or other condition that would interfere with intestinal absorption
- •No patients with clinically important history of liver disease, including viral or other hepatitis or cirrhosis
- •No prior history of malignancies other than lymphoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for >= 3 years
- •Must have recovered from adverse events due to agents administered more than 4 weeks earlier
- •Patients must have discontinued all prior therapies for at least 5 times the half-life of all prior anticancer therapies before study entry
- •Prior treatment could include high-dose chemotherapy with autologous stem-cell transplantation if patients had progressed >= 3 months after this treatment
- •No chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C)
- •Patients must not be receiving any other investigational agents
- •No other investigational or commercial agents or therapies may be administered with the intent to treat the patient's malignancy
- •No concurrent radiotherapy
排除标准
- 未提供
研究组 & 干预措施
Treatment (Akt inhibitor MK2206)
Experimental
Patients receive Akt inhibitor MK2206 PO once weekly on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: Akt Inhibitor MK2206 (Drug)
Treatment (Akt inhibitor MK2206)
Experimental
Patients receive Akt inhibitor MK2206 PO once weekly on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: Laboratory Biomarker Analysis (Other)
Treatment (Akt inhibitor MK2206)
Experimental
Patients receive Akt inhibitor MK2206 PO once weekly on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
干预措施: Pharmacological Study (Other)
结局指标
主要结局
Objective Response Rate According to the International Response Criteria for DLBCL (Cheson 2007)
时间窗: Up to 4 months
Rate of CR + PR according to Cheson 2007 after 4 months of treatment
次要结局
- Toxicity as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0(Up to 30 days)
- Progression-free Survival (PFS)(From the date of inclusion to the date of first documented disease progression, relapse or death from any cause, assessed up to 4 years)
- Overall Survival(From the date of inclusion to the date of death from any cause, assessed up to 4 years)
- Duration of Response(up to 4 years)
研究者
研究点 (9)
Loading locations...
相似试验
已完成
2 期
Study of Akt Inhibitor MK2206 in Patients With Relapsed LymphomaAdult Nasal Type Extranodal NK/T-cell LymphomaAngioimmunoblastic T-cell LymphomaB-cell Adult Acute Lymphoblastic LeukemiaB-cell Chronic Lymphocytic LeukemiaCutaneous B-cell Non-Hodgkin LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueHepatosplenic T-cell LymphomaIntraocular LymphomaNodal Marginal Zone B-cell LymphomaNoncutaneous Extranodal LymphomaPeripheral T-cell LymphomaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Hodgkin LymphomaRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeRecurrent Small Lymphocytic LymphomaRefractory Hairy Cell LeukemiaSmall Intestine LymphomaSplenic Marginal Zone LymphomaT-cell Adult Acute Lymphoblastic LeukemiaT-cell Large Granular Lymphocyte LeukemiaTesticular LymphomaWaldenström MacroglobulinemiaAnaplastic Large Cell LymphomaNCT01258998National Cancer Institute (NCI)60
已完成
2 期
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck CancerRecurrent Squamous Cell Carcinoma of the NasopharynxStage IV Squamous Cell Carcinoma of the NasopharynxNCT01349933National Cancer Institute (NCI)21
已完成
2 期
Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction CancerAdenocarcinoma of the Gastroesophageal JunctionDiffuse Gastric AdenocarcinomaGastric Intestinal Type AdenocarcinomaGastric Mixed AdenocarcinomaRecurrent Gastric CarcinomaNCT01260701National Cancer Institute (NCI)75
已完成
2 期
AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Recurrent Adult Acute Myeloid LeukemiaNCT01253447National Cancer Institute (NCI)19
已完成
2 期
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst CarcinomaRecurrent Oral Cavity Adenoid Cystic CarcinomaRecurrent Salivary Gland CarcinomaSalivary Gland Adenoid Cystic CarcinomaStage IVA Major Salivary Gland Cancer AJCC v7Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7Stage IVB Major Salivary Gland Cancer AJCC v7Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7Stage IVC Major Salivary Gland Cancer AJCC v7Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7NCT01604772National Cancer Institute (NCI)16